Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for irritable bowel syndrome
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
BE, Harris LA, et al. Am J Gastroenterol. 2019; 114(1):21-39. 2. Ruepert L, Quartero AO, de Wit NJ, et al. Cochrane Database Syst Rev. 2011; (8):CD003460. 3. Ford AC, Quigley EM, Lacy BE, et al. Am J Gastroenterol. 2014; 109(9):1350-65. 4. Moayyedi P, Andrews CN, MacQueen G, et al. J Can Assoc Gastroenterol. 2019; 2(1):6-29. 5. Canadian Digestive Health Foundation. IrritableBowelSyndrome. Available at: https://cdhf.ca/digestive-disorders/irritable-bowel-syndrome-ibs/what-is-irritable- bowel-syndrome (...) January 20, 2020 But I am not Depressed: Antidepressants for IrritableBowelSyndrome Clinical Question: Do antidepressant medications improve irritablebowelsyndrome (IBS) symptoms? Bottom Line: Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) may improve overall IBS symptoms. About 55% of patients treated with TCAs or SSRIs will benefit compared to ~35% with placebo. Only TCAs improve abdominal pain for ~60% of patients compared to ~30% with placebo. TCA
in IBS. Larger, more rigorously conducted trials of FMT in IBS are needed. M El-Salhy et al. Expert Rev Gastroenterol Hepatol 12 (5), 439-445. May 2018. PMID 29493330. - Review Irritablebowelsyndrome (IBS) is a widespread gastrointestinaldisorder affecting 11.2% of the world adult population. The intestinal microbiome is thought to play a piv … Show more similar articles Associated data ClinicalTrials.gov/NCT03822299 Actions LinkOut - more resources Full Text Sources Medical Full-text links [x] [x (...) bacterial profiles changed also significantly in the groups received FMT. The FMT adverse events were mild self-limiting gastrointestinal symptoms. Conclusions: FMT is an effective treatment for patients with IBS. Utilising a well-defined donor with a normal DI and favourable specific microbial signature is essential for successful FMT. The response to FMT increases with the dose. Trial registration www.clinicaltrials.gov ( ) and www.cristin.no (ID657402). Keywords: colonic microflora; irritablebowel
[Effect of healthy eating before intervention with a low FODMAP diet in pediatric patients with irritablebowelsyndrome]. Background: a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) may be effective in the treatment of pediatric patients with irritablebowelsyndrome (IBS). Its complexity and side effects make it a secondary therapeutic alternative. Objective: to demonstrate that nutritional education, aimed at optimizing the diet of children (...) with IBS, is able to improve gastrointestinal symptoms of children without following a diet low in FODMAP. Methods: prospective intervention study. Changes in gastrointestinal symptoms were analyzed by means of the Pediatric Quality of Life Inventory™ Gastrointestinal Symptoms (PedsQL™ GI Symptoms), after receiving nutritional education based on a healthy diet. Likewise, anthropometric changes and dietary habits were analyzed. Results: twenty-one patients were included (12 girls) with a mean age
Tenapanor (Ibsrela) - irritablebowelsyndrome with constipation in adults Drug Approval Package: IBSRELA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: IBSRELA Company: Ardelyx, Inc. Application Number: 211801 Approval Date: 09/12/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF
Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory BowelDisease, and IrritableBowelSyndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory BowelDisease, and IrritableBowelSyndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you (...) need Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory BowelDisease, and IrritableBowelSyndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Lyophilized versus Frozen Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection, Inflammatory BowelDisease, and IrritableBowelSyndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: August 14, 2019 Project
Summary of Recommendations of the American Gastroenterological Association on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant IrritableBowelSyndrome in Adults Statement Strength of recommendation Quality of evidence Recommendation 1: In patients presenting with chronic diarrhea, the AGA suggests the use of either fecal calprotectin or fecal lactoferrin to screen for IBD . Conditional Low Recommendation 2: In patients presenting with chronic diarrhea, the AGA suggests (...) Carrasco-Labra, A., Lytvyn, L., Falck-Ytter, Y. et al. AGA technical review on the evaluation of functional diarrhea and diarrhea-predominant irritablebowelsyndrome in adults (IBS-D). Gastroenterology . 2019 ; 157 : 859–880 | | | | | 5 Traveler’s Health. Travelers’ diarrhea. Centers for Disease Control and Prevention website. ( Available at: ) Date accessed: January 27, 2019 | 6 Riddle, M.S., Connor, B.A., Beeching, N.J. et al. Guidelines for the prevention and treatment of travelers' diarrhea
Homeopathy for treatment of irritablebowelsyndrome. Irritablebowelsyndrome (IBS) is a common, chronic disorder that leads to decreased health-related quality of life and work productivity. A previous version of this review was not able to draw firm conclusions about the effectiveness of homeopathic treatment for IBS and recommended that further high quality RCTs were conducted to explore the clinical and cost effectiveness of homeopathic treatment for IBS. Two types of homeopathic treatment (...) were evaluated in this systematic review: 1. Clinical homeopathy where a specific remedy is prescribed for a specific condition; 2. Individualised homeopathic treatment, where a homeopathic remedy based on a person's individual symptoms is prescribed after a detailed consultation.To assess the effectiveness and safety of homeopathic treatment for IBS.For this update we searched MEDLINE, CENTRAL, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Allied and Complementary
Efficacy and Safety of Eluxadoline in Patients With IrritableBowelSyndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study Irritablebowelsyndrome with diarrhea (IBS-D) is a functional gastrointestinaldisorder with limited effective treatment options. We evaluated the efficacy and safety of eluxadoline in patients with IBS-D who reported inadequate symptom control with prior loperamide.Three hundred forty-six adults with IBS-D (Rome III criteria (...) ) were randomly assigned to placebo or eluxadoline 100 mg twice daily for 12 weeks. Patients recorded daily IBS-D symptoms, including worst abdominal pain (WAP) and stool consistency (through Bristol Stool Scale). The primary endpoint was proportion of composite responders, defined as patients who met daily composite response criteria (≥40% WAP improvement and <5 Bristol Stool Scale score) for at least 50% of treatment days, and recorded ≥60 days of diary entries over the 12-week period.Over 12 weeks
Efficacy of Fecal Microbiota Transplantation in IrritableBowelSyndrome: A Systematic Review and Meta-Analysis Irritablebowelsyndrome (IBS) is a common gastrointestinalcondition with a heterogeneous pathophysiology. An altered gut microbiome has been identified in some IBS patients, and fecal microbiota transplantation (FMT) has been suggested to treat IBS. We performed meta-analyses and systematic review of available randomized controlled trials (RCTs) to evaluate the efficacy of FMT
Division of Gastroenterology, University of T oronto, T oronto, Ontario, Canada; 10 Division of Gastroenterology, Queen’s University, Kingston, Ontario, Canada Correspondence: Dr. Paul Moayyedi, BSc, MB, ChB, PhD, MPH, FRCP , FRCPC, AGAF, FACG, Director, Division of Gastroenterology, McMaster University, 1280 Main St. W . HSC 3V3, Hamilton, ON, Canada L8S 4K1, E-mail: firstname.lastname@example.org ABSTRACT Background & aims: Irritablebowelsyndrome (IBS) is one of the most common gastrointestinal (GI) disorders (...) /gwy071 Original Article Downloaded from https://academic.oup.com/jcag/advance-article-abstract/doi/10.1093/jcag/gwy071/5290372 by guest on 22 January 2019Irritable bowelsyndrome (IBS) is one of the most common gastrointestinal (GI) disorders. It is characterized by recurrent abdominal pain and altered bowel habits (i.e., constipation, diarrhea or both), often with associated bloating (1). Globally, IBS is estimated to affect about 10% of the general population, but prevalence rates are highly
be individualised and is dependent on the patient's predominant symptoms. Definition Irritablebowelsyndrome (IBS) is a chronic condition characterised by abdominal pain associated with bowel dysfunction. The pain is often relieved by defecation and is sometimes accompanied by abdominal bloating. There are no structural abnormalities to explain the pain. IBS occurs in about 15% of the adult population. The aetiology is probably multi-factorial and evidence suggests motility, inflammatory, genetic, immune (...) , psychological, and dietary components. Drossman DA, Camilleri M, Mayes FA. AGA technical review on irritablebowelsyndrome. Gastroenterology. 2002 Dec;123(6):2108-31. http://www.ncbi.nlm.nih.gov/pubmed/12454866?tool=bestpractice.com History and exam presence of risk factors abdominal discomfort alteration of bowel habits associated with pain abdominal bloating or distension normal examination of abdomen passage of mucus with stool physical and sexual abuse age <50 years female sex previous enteric
Efficacy of Secretagogues in Patients With IrritableBowelSyndrome With Constipation: Systematic Review and Network Meta-analysis Several secretagogues have been approved for the treatment of irritablebowelsyndrome with constipation (IBS-C). However, their relative efficacy is unclear because there have been no head-to-head randomized controlled trials. We conducted a network meta-analysis to compare their efficacies in patients with IBS-C.We searched MEDLINE, EMBASE, EMBASE Classic (...) according to their P score.We identified 15 eligible randomized controlled trials of secretagogues that included 8462 patients. Linaclotide, lubiprostone, plecanatide, and tenapanor were superior to placebo for the treatment of IBS-C. Linaclotide (290 μg once daily) was ranked first in efficacy based on the end point recommended by the Food and Drug Administration for trials in IBS-C, the primary end point used in each trial, abdominal pain, and complete spontaneous bowel movements. Tenapanor (50 mg
Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for IrritableBowelSyndrome: 12-Month Follow-Up There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education.A total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 (...) with negligible decay. For MC-CBT and S-CBT, 39 and 33% of respondents maintained treatment response at every follow-up assessment. The corresponding percent for EDU was 19%, which was significantly lower (p < 0.05) than for the CBT groups. On the IBS-SSS, therapeutic gains also showed a pattern of maintenance with trends towards increased efficacy over time in all conditions, with the mean unit reductions between baseline and follows-up being approximately -76 at immediate and approximately -94 at 12 months
manifests as recurrent flares of abdominal pain and bloody diarrhea along with periods of remission. Standard therapy has focused around maintenance and remission, rather than a cure. These lifelong diagnoses carry devastating consequences for patients. Modern medical therapy consists primarily of steroids, aminosalicylate anti-inflammatories and immunomodulators. IrritableBowelSyndrome (IBS) is one of the most common diagnoses in gastroenterology practices in the North American hemisphere. IBS shares (...) Curcumin as an Aid to Improve Symptoms of Inflammatory or IrritableBowelDiseases "Curcumin as an Aid to Improve Symptoms of Inflammatory or Irritable Bo" by Sarah Orscheln < > > > > > Title Author Date of Graduation Summer 8-11-2018 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Inflammatory boweldisease (IBD) is a poorly understood process that affects over a million people in the United States alone. The disease typically
Effect of Antidepressants and Psychological Therapies in IrritableBowelSyndrome: An Updated Systematic Review and Meta-analysis Irritablebowelsyndrome (IBS) is a chronic functional boweldisorder that is thought to be due to a disorder of brain-gut function. Drugs acting centrally, such as antidepressants, and psychological therapies may, therefore, be effective.We updated a previous systematic review and meta-analysis of randomized controlled trials (RCTs). MEDLINE, EMBASE, PsychINFO
Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritablebowelsyndrome More effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritablebowelsyndrome (IBS-D). Accordingly, we conducted a randomised, double-blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric (...) infection.Eligible adults were randomised to glutamine (5 g/t.i.d.) or placebo for 8 weeks. The primary end point was a reduction of ≥50 points on the IrritableBowelSyndrome Severity Scoring System (IBS-SS). Secondary endpoints included: raw IBS-SS scores, changes in daily bowel movement frequency, stool form (Bristol Stool Scale) and intestinal permeability.Fifty-four glutamine and 52 placebo subjects completed the 8-week study. The primary endpoint occurred in 43 (79.6%) in the glutamine group and 3 (5.8
on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com Top results for irritablebowelsyndrome 1. Probiotics for irritablebowelsyndrome 2017 2. IrritablebowelsyndromeIrritablebowelsyndrome - NICE CKS Clinical Knowledge Summaries Share Irritablebowelsyndrome - Summary Irritablebowelsyndrome ( IBS ) is a chronic, relapsing, and often lifelong disorder of gastrointestinal function (...) of irritablebowelsyndrome Poynard T, Regimbeau C, Benhamou Y Authors' objectives To assess the efficacy and tolerance of smooth muscle relaxants in the treatment of irritablebowelsyndrome ( IBS ). Searching A search of MEDLINE and a manual search were combined (...) . The keywords used were 'colonicdisease ', 'functional', irritablebowelsyndrome ' and 'randomised trial'. Additional studies were obtained by examining general reviews, references from published RCTs, and Current Contents
A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of IrritableBowelSyndrome Dietary triggers such as gluten and highly fermentable oligo-, di- and monosaccharides and polyols (FODMAP)-containing foods have been associated with worsening irritablebowelsyndrome (IBS) symptoms. However, the true impact of dietary restriction on IBS symptoms has remained unclear. The aim of this study was to conduct a systematic (...) screened citations and a third reviewer resolved disagreement. Two independent reviewers performed eligibility assessment and data abstraction. For inclusion, RCTs that evaluated an exclusion diet versus an alternative or usual diet and assessed improvement in either global IBS symptoms or abdominal pain were required. Data were synthesized as relative risk of symptoms remaining using a random effects model. Quality of evidence was assessed using GRADE methodology.A total of 1726 citations were
Faecal microbiota transplantation alters gut microbiota in patients with irritablebowelsyndrome: results from a randomised, double-blind placebo-controlled study IBS is associated with an intestinal dysbiosis and faecal microbiota transplantation (FMT) has been hypothesised to have a positive effect in patients with IBS. We performed a randomised, double-blind placebo-controlled trial to investigate if FMT resulted in an altered gut microbiota and improvement in clinical outcome in patients